We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Trial Investigating NN1218 in Subjects With Type 1 Diabetes

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01121289
First Posted: May 12, 2010
Last Update Posted: December 10, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Novo Nordisk A/S
May 10, 2010
May 12, 2010
December 10, 2013
April 2010
July 2010   (Final data collection date for primary outcome measure)
Area under the serum NN1218 concentration-time curve [ Time Frame: From 0-1 hours ]
Same as current
Complete list of historical versions of study NCT01121289 on ClinicalTrials.gov Archive Site
Area under the serum NN1218 concentration-time curve [ Time Frame: From 0-10 hours ]
Same as current
Not Provided
Not Provided
 
A Trial Investigating NN1218 in Subjects With Type 1 Diabetes
A Trial Investigating the Pharmacokinetic Properties of NN1218 in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate the absorption and effect in the body of NN1218 in subjects with type 1 diabetes.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
  • Diabetes
  • Diabetes Mellitus, Type 1
  • Drug: NN1218
    0.2 U/kg body weight injected subcutaneously (under the skin)
  • Drug: insulin aspart
    0.2 U/kg body weight injected subcutaneously (under the skin)
  • Drug: NN1218
    0.4 U/kg body weight injected subcutaneously (under the skin)
  • Experimental: NN1218, formulation A
    Intervention: Drug: NN1218
  • Experimental: NN1218, formulation B
    Intervention: Drug: NN1218
  • Experimental: NN1218, formulation B (high)
    Intervention: Drug: NN1218
  • Experimental: NN1218, formulation C
    Intervention: Drug: NN1218
  • Experimental: NN1218, formulation D
    Intervention: Drug: NN1218
  • Active Comparator: insulin aspart
    Intervention: Drug: insulin aspart
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
26
July 2010
July 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Type 1 diabetes mellitus for more than 12 months
  • Treated with multiple daily insulin injections or continuous subcutaneous insulin infusion (CSII) for more than 12 months
  • Body mass index (BMI) between 18.0-28.0 kg/m2 (both inclusive)

Exclusion Criteria:

  • Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to trial start
  • Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day)
  • Not able or willing to refrain from smoking and use of nicotine gum or transdermal nicotine patches during the inpatient period
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
 
NCT01121289
NN1218-3808
U1111-1113-6955 ( Other Identifier: WHO )
2009-017121-19 ( EudraCT Number )
No
Not Provided
Not Provided
Novo Nordisk A/S
Novo Nordisk A/S
Not Provided
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
Novo Nordisk A/S
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP